Article Text

Download PDFPDF
Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
  1. María Del Pilar Briceño-Casado1,
  2. Manuel David Gil-Sierra2,3,
  3. Beatriz De-La-Calle-Riaguas1
  1. 1Pharmacy, Hospital General Nuestra Señora del Prado, Talavera de la Reina, Castilla-La Mancha, Spain
  2. 2Department of Pharmacology, Universidad de Sevilla, Sevilla, Spain
  3. 3Pharmacy, Hospital Doctor José Molina Orosa, Lanzarote, Las Palmas, Spain
  1. Correspondence to Dr María Del Pilar Briceño-Casado, Pharmacy, Hospital General Nuestra Señora del Prado, 45600 Talavera de la Reina, Castilla-La Mancha, Spain; pilarbricenocasado{at}gmail.com

Abstract

A multicentre case series of patients with chronic migraine (CM) treated with monoclonal antibodies directed against calcitonin gene-related peptide (CGRP-mAbs) switching were developed. The effectiveness and safety of CGRP-mAbs switching as a preventive treatment for CM in clinical practice were recorded. Effectiveness was measured by ≥50% reduction of monthly migraine days in respect to baseline and reduction in pain intensity. Safety was analysed through adverse events (AEs) and treatment discontinuations. Seven patients were included. The reason for switching was non-response in all cases. Two patients presented a response to the first CGRP-mAb, but the effect was lost after 3 months. The remaining five patients were non-responders. Response to the second CGRP-mAb was observed in three patients, one of them for >3 months. Less than half of the patients previously treated with a CGRP-mAb responded to switching with a second CGRP-mAb. AEs were rare, with no treatment discontinuations.

  • drug substitution
  • quality of health care
  • safety
  • neurology
  • pain management

Data availability statement

All data relevant to the study are included in the article.

Statistics from Altmetric.com

Data availability statement

All data relevant to the study are included in the article.

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.